Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9356159 | 0.85 | KDM4E (0.43) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL31591148 | 0.85 | KDM4E (0.67) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2352264 | 0.85 | KDM4E (0.67) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL21200377 | 0.84 | KDM4E (0.59) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL7662023 | 0.83 | KDM4E (0.64) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL1054149 | 0.82 | NPSR1 (0.44) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2829094 | 0.82 | PIM1 (0.44) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL30952862 | 0.82 | NPSR1 (0.44) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL31443034 | 0.82 | KDM4E (0.61) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL15057886 | 0.82 | KDM4E (0.61) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120157917-A | Preparation method of PET bottle flake regenerated crease-resistant fiber master batch | 江苏衣生缘生物科技有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-119959198-A | Preparation method of fluorescent metal-organic framework test paper for detecting sulfur hexafluoride and application of fluorescent metal-organic framework test paper in detecting trace sulfur hexafluoride | 东北电力大学 | 2025-05-09 | — | — | CN | claimed |
| CN-117757432-B | High-suspension grinding fluid suitable for large-size silicon wafer, preparation method and application | 江苏奥首材料科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118415347-A | Composition and preparation for promoting growth and development of children as well as preparation method and application of composition and preparation | 安徽华恒生物科技股份有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-117757432-A | High-suspension grinding fluid suitable for large-size silicon wafer, preparation method and application | 江苏奥首材料科技有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-111634908-B | Method for preparing porous carbon by nitrogen and oxygen co-doping porous carbon and L-lysine and application | 山东大学 | 2022-03-01 | — | — | CN | claimed |
| US-9359297-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2016-06-07 | — | — | US | claimed |
| CN-102595893-B | Spirolactam derivatives and uses of same | LUNDBECK & CO AS H | 2014-12-31 | — | — | CN | claimed |
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | US | claimed |
| EP-2493304-B1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | claimed |
| US-8633190-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-01-21 | — | — | US | claimed |
| CN-102595893-A | Spirolactam derivatives and uses of same | LUNDBECK & CO AS H | 2012-07-18 | — | — | CN | claimed |
| US-12616674-B2 | Anti-fibrotic NEU3 inhibitor compounds and methods of use | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2026-05-05 | — | — | US | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250353796-A1 | LIQUID PRODUCTS HAVING INCREASED SOLIDS CONCENTRATIONS | ARCHER DANIELS MIDLAND CO (US) | 2025-11-20 | — | — | US | disclosed |
| US-12440463-B2 | Modified release orally administered amino acid formulations | APR APPLIED PHARMA RESEARCH S.A. (CH) | 2025-10-14 | — | — | US | disclosed |
| US-6107297-A | 2,4-Dithi(oxo)-pyrimidin-5-yl compounds bearing a tricyclic substituent useful as P2 purinoceptor antagonists | ASTRA PHARMACEUTICALS LIMITED (GB) | 2000-08-22 | — | — | US | disclosed |
| EP-0996617-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999002501-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-01-21 | — | — | WO | disclosed |
| WO-1998022148-A1 | MRI CONTRAST AGENTS AND LIGANDS | WASHINGTON UNIVERSITY (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | REN, AGTR1, PDE6D | KDM4E 3581/4885ALOX15 3251/4885TSHR 549/4885 |
| US-12616674-B2 | Anti-fibrotic NEU3 inhibitor compounds and methods of use | NEU3, NEU2, NEU1 | KDM4E 2867/4885ALOX15 1030/4885TSHR 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.